Delivery Order SPE2DR25D1109-SPE2DR26FFJ2N
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $11,174.80 for 100-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic medical applications. This non-set-aside, competitively awarded contract employs firm fixed pricing and is scheduled for completion by November 17, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $1,472.05 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic medical applications. The award, issued on December 1, 2025, with a completion date of December 22, 2025, represents a non-set-aside competitive procurement. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $1,676.22 delivery order to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product commonly used for therapeutic and cosmetic medical applications. This firm fixed-price delivery order, issued on September 2, 2025, with an ultimate completion date of September 23, 2025, represents a child contract under AmerisourceBergen's larger pharmaceutical supply agreement. The award was made through open competition with no set-aside...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,587.40 to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin product used for medical and therapeutic purposes. This firm fixed-price delivery order, issued on September 15, 2025, with an ultimate completion date of October 6, 2025, represents a non-set-aside competitive award to the prime contractor. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $5,587.40 for 100-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic applications. This non-set-aside, firm fixed-price delivery order was awarded on October 30, 2025, with an ultimate completion date of November 21, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $8,381.10 to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin-based therapeutic product used for medical applications. This non-set-aside, competitively awarded contract is issued under a firm fixed price structure with an ultimate completion date of September 19, 2025. The order will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania facility, where the company maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $5,888.20 to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin-based pharmaceutical product. This firm fixed-price delivery order, issued on December 3, 2025, with an ultimate completion date of December 24, 2025, represents a non-competitive set-aside award to the pharmaceutical distributor. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $49,461.72 delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic applications. This firm fixed-price contract, awarded November 5, 2025, with completion targeted for November 28, 2025, represents a competitively awarded procurement with no set-aside designation. The order will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania facility, where the company...
- The Defense Logistics Agency awarded a $10,057.32 delivery order to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic medical applications. This firm fixed-price delivery order was competitively awarded without set-aside designation and is scheduled for completion by October 30, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,352.44 to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin injection used for medical and therapeutic purposes. The contract, awarded on November 6, 2025, with an ultimate completion date of December 1, 2025, represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where...
- SPE2DR25D1109Indefinite Delivery Contract
- SPE2DR25D1109-SPE2DR26FFJ2NDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $17,664.90 to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin product used in medical and therapeutic applications. This firm fixed-price delivery order, issued on December 17, 2025, with an ultimate completion date of January 9, 2026, was competitively awarded with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. As a prime vendor under this comprehensive global pharmaceutical support vehicle, AmerisourceBergen supplies a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including the Defense Health Agency and U.S. Coast Guard. The company's established role as a critical federal pharmaceutical distributor is reflected in its consistent receipt of competitively awarded delivery orders spanning multiple therapeutic domains and product categories.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $17.7k | 12/16/25 |